scispace - formally typeset
A

Ann C. Mertens

Researcher at Emory University

Publications -  116
Citations -  16029

Ann C. Mertens is an academic researcher from Emory University. The author has contributed to research in topics: Childhood Cancer Survivor Study & Cancer. The author has an hindex of 55, co-authored 93 publications receiving 14793 citations. Previous affiliations of Ann C. Mertens include University of Kentucky & University of Minnesota.

Papers
More filters
Journal ArticleDOI

Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study

TL;DR: While recurrent disease remains a major contributor to late mortality in 5-year survivors of childhood cancer, significant excesses in mortality risk associated with treatment-related complications exist up to 25 years after the initial cancer diagnosis.
Journal ArticleDOI

Second Malignant Neoplasms in Five-Year Survivors of Childhood Cancer: Childhood Cancer Survivor Study

TL;DR: Success in treating children with cancer should not be overshadowed by the incidence of SMNS, but patients and health-care providers must be aware of risk factors for SMNs so that surveillance is focused and early prevention strategies are implemented.
Journal ArticleDOI

Cause-Specific Late Mortality Among 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor Study

TL;DR: At 20 years of follow-up (25 years after first cancer diagnosis), the death rate due to a subsequent malignancy exceeded that due to all other causes and indicates that excess mortality persists long after diagnosis.
Journal ArticleDOI

Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project.

TL;DR: The Childhood Cancer Survivor Study (CCSS) as discussed by the authors is a large, diverse, and well-characterized cohort of 5-year survivors of childhood and adolescent cancer, which includes a selected group of cancer diagnoses prior to age 21 years between 1970-1986 and survival for at least 5 years.